Menu
Search
|

Menu

Close
X

Sunesis Pharmaceuticals Inc SNSS.OQ (NASDAQ Stock Exchange Capital Market)

2.42 USD
+0.01 (+0.41%)
As of Jul 21
chart
Previous Close 2.41
Open 2.41
Volume 37,507
3m Avg Volume 48,488
Today’s High 2.47
Today’s Low 2.41
52 Week High 7.68
52 Week Low 1.84
Shares Outstanding (mil) 23.51
Market Capitalization (mil) 56.67
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.67 Mean rating from 3 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
1
FY16
3
FY15
3
EPS (USD)
FY18
-0.212
FY17
-1.516
FY16
-2.478
FY15
-3.019
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
28.99
5.73
Price to Book (MRQ)
vs sector
--
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
56.85
16.84
LT Debt to Equity (MRQ)
vs sector
43.49
12.51
Return on Investment (TTM)
vs sector
-174.35
14.61
Return on Equity (TTM)
vs sector
--
16.34

EXECUTIVE LEADERSHIP

James Young
Non-Executive Independent Chairman of the Board, Since 2009
Salary: --
Bonus: --
Dayton Misfeldt
Interim Chief Executive Officer, Director, Since 2018
Salary: --
Bonus: --
William Quinn
Chief Financial Officer, Senior Vice President - Finance and Corporate Development, Since 2017
Salary: --
Bonus: --
Adam Craig
Executive Vice President - Development, Chief Medical Officer, Since 2012
Salary: $420,938.00
Bonus: --
Stephen Ketchum
Director, Since 2012
Salary: $46,250.00
Bonus: $11,250.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

395 Oyster Point Blvd Ste 400
SOUTH SAN FRANCISCO   CA   94080-1995

Phone: +1650.2663500

Sunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company's other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.

SPONSORED STORIES